NCT06925737
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06925737
Title A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | FRA | ESP | DNK | DEU | CZE | CHE | BRA | AUT | AUS | ARG


No variant requirements are available.